Abayomi, O.K. (2002). Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta Oncologica, 41, 346-351.
Ahles, T.A., & Saykin, A. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigation, 19, 812-820.
Ahles, T.A., & Saykin, A.J. (2002). Breast cancer chemotherapy-related cognitive dysfunction. Clinical Breast Cancer, 3(Suppl. 3), S84-S90.
Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L. A., Skalla, K., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.
Ahles, T.A., Saykin, A.J., Noll, W.W., Furstenberg, C.T., Guerin, S., Cole, B., et al. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12, 612-619.
Ahles, T.A., Silberfarb, P.M., Herndon, J., II, Maurer, L.H., Kornblith, A.B., Aisner, J., et al. (1998). Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukemia Group B. Journal of Clinical Oncology, 16, 1954-1960.
Andersen, B.L. (2002). Biobehavioral outcomes following psychological interventions for cancer patients. Journal of Consulting and Clinical Psychology, 70, 590-610.
Anderson-Hanley, C., Sherman, M.L., Riggs, R., Agocha, V.B., & Compas, B.E. (2003). Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. Journal of the International Neuropsychological Society, 9, 967-982.
Aziz, N., & Krouse, R. (2005). Cancer survivorship. In D.S. Alberts & L.M. Hess (Eds.), Fundamentals of cancer prevention (pp. 363-391). Heidelberg: Springer Verlag.
Baron, R.M. & Kenny, D.A. (1986). The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology, 51, 1173-1182.
Barton, D., & Loprinzi, C. (2002). Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: The art of the possible. Clinical Breast Cancer, 3(Suppl. 3), S121-S127.
Bender, C.M., Paraska, K.K., Sereika, S.M., Ryan, C.M., & Berga, S.L. (2001). Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. Journal of Pain and Symptom Management, 21, 407-424.
Bennett, D.A., Wilson, R.S., Schneider, J.A., Evans, D.A., Mendes de Leon, C.F., Arnold, S.E., et al. (2003). Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology, 60, 1909-1915.
Brezden, C.B., Phillips, K.A., Abdolell, M., Bunston, T. & Tannock, I.F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701.
Chaiken, S.R., Kyllonen, P.C., & Tirre, W.C. (2000). Organization and components of psychomotor ability. Cognitive Psychology, 40, 198-226.
Chang, E.L., & Lo, S. (2003). Diagnosis and management of central nervous system metastases from breast cancer. Oncologist, 8, 398-410.
Cimprich, B., & Ronis, D.L. (2001). Attention and symptom distress in women with and without breast cancer. Nursing Research, 50, 86-94.
Cimprich, B., So, H., Ronis, D.L., & Trask, C. (2005). Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology, 14, 70-78.
Coons, S.J., & Craig, B.M. (2005). Assessing human and economic benefits of cancer prevention. In D. S. Alberts & L.M. Hess (Eds.), Fundamentals of cancer prevention (pp. 11-24). Heidelberg: Springer-Verlag.
Cull, A., Hay, C., Love, S.B., Mackie, M., Smets, E., & Stewart, M. (1996). What do cancer patients mean when they complain of concentration and memory problems? British Journal of Cancer, 74, 1674-1679.
Cunningham, R.S. (2003). Anemia in the oncology patient: Cognitive function and cancer. Cancer Nursing, 26(Suppl. 6), 38S-42S.
Davidson, J.E., & Downing, C.L. (2000). Contemporary models of intelligence. In R.J. Sternberg (Ed.), Handbook of intelligence. New York: Cambridge University Press.
Degl'Innocenti, A., Elmfeldt, D., Hansson, L., Breteler, M., James, O., Lithell, H., et al. (2002). Cognitive function and health-related quality of life in elderly patients with hypertension—Baseline data from the Study on Cognition and Prognosis in the Elderly (SCOPE). Blood Pressure, 11, 157-165.
Degner, L.F., Hack, T., O'Neil, J., & Kristjanson, L.J. (2003). A new approach to eliciting meaning in the context of breast cancer. Cancer Nursing, 26, 169-178.
Erlanger, D.M., Feldman, D.J., Kaplan, D., and Theodoracopulos, A. (2000). Development and validation of the cognitive stability index, a web-based protocol for monitoring change in cognitive function. Archives of Clinical Neuropsychology, 15, 693-694.
Fliessbach, K., Urbach, H., Helmstaedter, C., Pels, H., Glasmacher, A., Kraus, J.A., et al. (2003). Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Archives of Neurology, 60, 563-568.
Foster, L.W., & McLellan, L. (2000). Cognition and the cancer experience: Clinical implications. Cancer Practice, 8, 25-31.
Frytak, S., Shaw, J.N., Lee, R.E., Eagan, R.T., Shaw, E.G., Richardson, R.L., et al. (1988). Treatment toxicities in long-term survivors of limited small cell lung cancer. Cancer Investigation, 6, 669-676.
Gottschalk, L.A., Holcombe, R.F., Jackson, D., & Bechtel, R.J. (2003). The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods and Findings in Experimental and Clinical Pharmacology, 25, 117-122.
Graves, K.D. (2003). Social cognitive theory and cancer patients' quality of life: A meta-analysis of psychosocial intervention components. Health Psychology, 22, 210-219.
Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
Hensley, M.L., Correa, D.D., Thaler, H., Wilton, A., Venkatraman, E., Sabbatini, P., et al. (2006). Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic Oncology, 102, 270-277.
Hurria, A., Goldfarb, S., Rosen, C., Holland, J., Zuckerman, E., Lachs, M.S., et al. (2006). Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Research and Treatment, 98, 343-348.
Jacobsen, P.B., Garland, L.L., Booth-Jones, M., Donovan, K.A., Thors, C.L., Winters, E., et al. (2004). Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. Journal of Pain and Symptom Management, 28, 7-18.
Jansen, C., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005a). A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer, 104, 2222-2233.
Jansen, C., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005b). Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncology Nursing Forum, 32, 1151-1163.
Joly, F., Alibhai, S.M., Galica, J., Park, A., Yi, Q.L., Wagner, L., et al. (2006). Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. Journal of Urology, 176, 2443-2447.
Kaplan, C.P., & Miner, M.E. (1998). Does the SCL 90-R obsessive-compulsive dimension identify cognitive impairments? Journal of Head Trauma Rehabilitation, 13(3), 94-101.
Keime-Guibert, F., Napolitano, M., & Delattre, J.Y. (1998). Neurological complications of radiotherapy and chemotherapy. Journal of Neurology, 245, 695-708.
Kiessling, A., & Henriksson, P. (2004). Perceived cognitive function is a major determinant of health related quality of life in a non-selected population of patients with coronary artery disease—A principal components analysis. Quality of Life Research, 13, 1621-1631.
Klepstad, P., Hilton, P., Moen, J., Fougner, B., Borchgrevink, P.C., & Kaasa, S. (2002). Self-reports are not related to objective assessments of cognitive function and sedation in patients with cancer pain admitted to a palliative care unit. Palliative Medicine, 16, 513-519.
Komaki, R., Meyers, C.A., Shin, D.M., Garden, A.S., Byrne, K., Nickens, J.A., et al. (1995). Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. International Journal of Radiation Oncology Biology and Physics, 33, 179-182.
Licinio, J., Kling, M.A., & Hauser, P. (1998). Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes. Seminars in Oncology, 25(Suppl. 1), 30-38.
Lilja, A.M., Portin, R.I., Hamalainen, P.I., & Salminen, E.K. (2001). Short-term effects of radiotherapy on attention and memory performances in patients with brain tumors. Cancer, 91, 2361-2368.
Massa, E., Madeddu, C., Lusso, M.R., Gramignano, G., & Mantovani, G. (2006). Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Critical Reviews in Oncology/Hematology, 57, 175-182.
Matlin, M.W. (2003). Cognition. Geneseo, NY: John Wiley and Sons.
Mayerhofer, K., Bodner-Adler, B., Bodner, K., Saletu, B., Schindl, M., Kaider, A., et al. (2000). A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: A prospective study in patients with ovarian cancer. Anticancer Research, 20(5C), 4051-4055.
McCracken, L.M., & Iverson, G.L. (2001). Predicting complaints of impaired cognitive functioning in patients with chronic pain. Journal of Pain and Symptom Management, 21, 392-396.
Meyers, C.A. (2000). Neurocognitive dysfunction in cancer patients. Oncology, 14, 75-79.
Meyers, C.A., & Wefel, J.S. (2003). The use of the mini-mental state examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. Journal of Clinical Oncology, 21, 3557-3558.
Miller, I.E. (1909). The psychology of thinking. New York: MacMillan Company.
Miller, K.D. (2001). Chemotherapy and cognitive function: Maybe its all in their heads? 37th Annual Meeting of the American Society of Clinical Oncology Breast Cancer CME. Retrieved January 31, 2007 http://www.medscape.com/viewarticle/418462
Mitchell, R.L., & Phillips, L.H. (2007). The psychological, neurochemical and functional neuroanatomical mediators of the effects of positive and negative mood on executive functions. Neuropsychologia, 45, 617-629.
Miyake, A., Friedman, N.P., Rettinger, D.A., Shah, P., & Hegarty, M. (2001). How are visuospatial working memory, executive functioning, and spatial abilities related? A latent-variable analysis. Journal of Experimental Psychology: General, 130, 621-640.
Moher, D., Cook, D.J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D.F. (2000). Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. British Journal of Surgery, 87, 1448-1454.
Moher, D., Schulz, K.F., & Altman, D. (2005). The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY), 1, 40-45.
Olin, J.J. (2001). Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park), 15, 613-618.
O'Shaughnessy, J.A. (2002). Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clinical Breast Cancer, 3(Suppl. 3), S116-S120.
Paganini-Hill, A., & Clark, L.J. (2000). Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment, 64, 165-176.
Paraska, K., & Bender, C.M. (2003). Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncology Nursing Forum, 30, 473-478.
Phillips, K.A., & Bernhard, J. (2003). Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. Journal of the National Cancer Institute, 95, 190-197.
Salminen, E., Portin, R., Korpela, J., Backman, H., Parvinen, L.M., Helenius, H., et al. (2003). Androgen deprivation and cognition in prostate cancer. British Journal of Cancer, 89, 971-976.
Salminen, E.K., Portin, R.I., Koskinen, A.I., Helenius, H.Y., & Nurmi, M.J. (2005). Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer, 103, 1381-1387.
Saykin, A.J., Ahles, T.A., & McDonald, B.C. (2003). Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, patho-physiological, and neuroimaging perspectives. Seminars in Clinical Neuropsychiatry, 8, 201-216.
Schagen, S.B., Hamburger, H.L., Muller, M.J., Boogerd, W., & van Dam, F.S. (2001). Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. Journal of Neuro-Oncology, 51, 159-165.
Schagen, S.B., Muller, M.J., Boogerd, W., Mellenbergh, G.J., & van Dam, F.S. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98, 1742-1745.
Schagen, S.B., Muller, M.J., Boogerd, W., Rosenbrand, R.M., van Rhijn, D., Rodenhuis, S., et al. (2002). Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Annals of Oncology, 13, 1387-1397.
Schagen, S.B., van Dam, F.S., Muller, M.J., Boogerd, W., Lindeboom, J., & Bruning, P.F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
Shilling, V., Jenkins, V., Fallowfield, L., & Howell, T. (2003). The effects of hormone therapy on cognition in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 86, 405-412.
Silberfarb, P.M. (1983). Chemotherapy and cognitive defects in cancer patients. Annual Review of Medicine, 34, 35-46.
Silberfarb, P.M., Philibert, D., & Levine, P.M. (1980). Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. American Journal of Psychiatry, 137, 597-601.
Sjogren, P., Olsen, A.K., Thomsen, A.B., & Dalberg, J. (2000). Neuropsychological performance in cancer patients: The role of oral opioids, pain and performance status. Pain, 86, 237-245.
Smith, G.E., Petersen, R.C., Parisi, J.E., Ivnik, R.J., Kokmen, E., Tangalos, E.G., et al. (1996). Definition, course, and outcome of mild cognitive impairment. Aging, Neuropsychology, and Cognition, 3, 141-147.
Smith, M.Y., Redd, W.H., Peyser, C., & Vogl, D. (1999). Post-traumatic stress disorder in cancer: A review. Psycho-Oncology, 8, 521-537.
Staat, K., & Segatore, M. (2005). The phenomenon of chemo brain. Clinical Journal of Oncology Nursing, 9, 713-721.
Sweet, J.J., Doninger, N.A., Zee, P.C., & Wagner, L.I. (2004). Factors influencing cognitive function, sleep, and quality of life in individuals with systemic lupus erythematosus: A review of the literature. Clinical Neuropsychology, 18, 132-147.
Tannock, I.F., Ahles, T.A., Ganz, P.A., & van Dam, F.S. (2004). Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. Journal of Clinical Oncology, 22, 2233-2239.
Taylor, B.V., Buckner, J.C., Cascino, T.L., O'Fallon, J.R., Schaefer, P.L., Dinapoli, R.P., et al. (1998). Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma [see comment]. Journal of Clinical Oncology, 16, 2195-2201.
Tchen, N., Juffs, H.G., Downie, F.P., Yi, Q.L., Hu, H., Chemerynsky, I., et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.
van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., vd Wall, E., Droogleever Fortuyn, M.E., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
Vardy, J., Wong, K., Yi, Q.L., Park, A., Maruff, P., Wagner, L., et al. (2006). Assessing cognitive function in cancer patients. Supportive Care in Cancer, 14, 1111-1118.
Vas, C.J., Rajkumar, S., Tanyakitpisal, P., & Chandra, V. (2002). Alzheimer's disease: Of emerging importance. Regional Health Forum, 6(1), 39-48.
Walker, L.G., Wesnes, K.P., Heys, S.D., Walker, M.B., Lolley, J., & Eremin, O. (1996). The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerised assessments. European Journal of Cancer, 32A, 2275-2283.
Walker, L.O., & Avant, K.C. (2005). Strategies of theory construction in nursing. Upper Saddle River, NJ: Pearson Education.
Wallberg, B., Michelson, H., Nystedt, M., Bolund, C., Degner, L., & Wilking, N. (2003). The meaning of breast cancer. Acta Oncologica, 42, 30-35.
Wefel, J.S., Kayl, A.E., & Meyers, C.A. (2004). Neuropsychological dysfunction associated with cancer and cancer therapies: A conceptual review of an emerging target. British Journal of Cancer, 90, 1691-1696.
Wefel, J.S., Lenzi, R., Theriault, R., Buzdar, A.U., Cruickshank, S., & Meyers, C.A. (2004). ‘Chemobrain’ in breast carcinoma? A prologue. Cancer, 101, 466-475.
Wieneke, M.H., Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66.
Wight, R.G., Aneshensel, C.S., & Seeman, T.E. (2002). Educational attainment, continued learning experience, and cognitive function among older men. Journal of Aging and Health, 14, 211-236.